中海石油化學(03983.HK)預期2024年淨利10.5億元至10.9億元
格隆匯2月27日丨中海石油化學(03983.HK)公吿,集團截至2024年12月31日止年度,在國際財務報吿會計準則下將錄得公司擁有人權益應占淨利潤約人民幣10.5億元至人民幣10.9億元,而截至2023年12月31日止年度公司擁有人權益應占淨利潤約人民幣23.82億元。
截至2023年12月31日止年度,公司擁有人權益應占淨利潤包含出售中石油(內蒙古)新材料有限責任公司(前稱中海石油天野化工有限責任公司)67%的股權("出售")產生的收益人民幣852百萬元。除去出售的影響,截至2024年12月31日止年度的公司擁有人權益應占淨利潤預期仍將同比減少,主要因為公司今年三套尿素裝置集中檢修導致的尿素產銷量降低以及公司尿素等主要產品價格大幅下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.